Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Tocchetti
A
A
Tambini
R
R
Allegro
A
A
Longoni
E
E
Rinaldi
E
E
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010419:Pentamidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013415:Sulfalene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016781:Toxoplasmosis, Cerebral / Q000517:prevention & control*; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D013415:Sulfalene; D011739:Pyrimethamine